The estimated Net Worth of Marc Wilson is at least $8.94 millió dollars as of 25 July 2024. Mr. Wilson owns over 19,056 units of Crinetics Pharmaceuticals Inc stock worth over $6,603,710 and over the last 9 years he sold CRNX stock worth over $915,394. In addition, he makes $1,423,810 as Chief Financial Officer at Crinetics Pharmaceuticals Inc.
Sign up
Mr. Wilson CRNX stock SEC Form 4 insiders trading
Marc has made over 7 trades of the Crinetics Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 19,056 units of CRNX stock worth $176,840 on 25 July 2024.
The largest trade he's ever made was exercising 32,129 units of Crinetics Pharmaceuticals Inc stock on 28 June 2024 worth over $298,157. On average, Marc trades about 8,378 units every 25 days since 2016. As of 25 July 2024 he still owns at least 130,148 units of Crinetics Pharmaceuticals Inc stock.
You can see the complete history of Mr. Wilson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Marc Wilson biography
Marc Wilson CPA serves as Chief Financial Officer of the Company. Prior to Crinetics, Mr. Wilson was Vice President of Finance and Accounting and Chief Accounting Officer at Cidara Therapeutics, Inc., a publicly-traded biotechnology company, from September 2014 to January 2018. Prior to Cidara, from October 2010 to August 2014, Mr. Wilson was Director of Accounting and Controller at Trius Therapeutics, a biopharmaceutical company, until its acquisition by Cubist Pharmaceuticals. Prior to Trius, Mr. Wilson worked at Neurocrine Biosciences, Inc. from 2007 to 2010. Mr. Wilson began his career in 2001 with PricewaterhouseCoopers LLP and is a certified public accountant. Mr. Wilson earned a bachelor’s degree in Economics and Accounting from the College of the Holy Cross.
What is the salary of Marc Wilson?
As the Chief Financial Officer of Crinetics Pharmaceuticals Inc, the total compensation of Marc Wilson at Crinetics Pharmaceuticals Inc is $1,423,810. There are 2 executives at Crinetics Pharmaceuticals Inc getting paid more, with R. Scott Struthers having the highest compensation of $3,766,660.
How old is Marc Wilson?
Marc Wilson is 41, he's been the Chief Financial Officer of Crinetics Pharmaceuticals Inc since 2018. There are 17 older and 1 younger executives at Crinetics Pharmaceuticals Inc. The oldest executive at Crinetics Pharmaceuticals Inc is Wendall Wierenga, 72, who is the Independent Chairman of the Board.
What's Marc Wilson's mailing address?
Marc's mailing address filed with the SEC is C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO, CA, 92121.
Insiders trading at Crinetics Pharmaceuticals Inc
Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over $52,514,606 worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth $62,800,483 . The most active insiders traders include Advisors Llcperceptive Life..., Jack Nielsen és Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $3,116,248. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth $159,570.
What does Crinetics Pharmaceuticals Inc do?
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
What does Crinetics Pharmaceuticals Inc's logo look like?
Complete history of Mr. Wilson stock trades at Cidara Therapeutics Inc és Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc executives and stock owners
Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
R. Scott Struthers,
President, Chief Executive Officer, Director -
Alan Krasner,
Chief Medical Officer -
Marc Wilson,
Chief Financial Officer -
Dr. R. Scott Struthers Ph.D.,
Founder, Pres, CEO & Director -
Dr. Ajay Madan DABT, Ph.D., D.A.B.T.,
Chief Devel. Officer -
Marc J. C. Wilson,
CFO & Sec. -
Stephanie Okey,
Independent Director -
Wendall Wierenga,
Independent Chairman of the Board -
Matthew Fust,
Independent Director -
Jeff E. Knight,
Chief Operating Officer -
Stephen Kaldor,
Independent Director -
Weston Nichols,
Independent Director -
Peter Trainer,
Vice President - Clinical Endocrinology -
Camille Bedrosian,
Independent Director -
Adriana Cabre,
Vice President of Human Resources -
Ajay Madan,
Chief Development Officer -
Chris Robillard M.B.A.,
Chief Bus. Officer -
James Hassard,
Chief Commercial Officer -
Dr. Alan S. Krasner M.D.,
Chief Medical Officer -
Adriana Cabre M.B.A.,
Chief HR Officer -
Kevin Capps,
Head of Intellectual Property -
Dr. Alan S. Krasner,
Chief Medical Officer -
Garlan Adams,
Gen. Counsel -
Dr. Stephen F. Betz Ph.D.,
Founder & Chief Scientific Officer -
Dr. Yun-Fei Zhu,
Founder & VP of Chemistry -
Jeff E. Knight,
Chief Operating Officer -
Advisors Llcperceptive Life...,
-
Capital Viii, Llc Vivo Capi...,
-
Venture Capital V, L.P.Vers...,
-
Capital Viii, Llc Vivo Capi...,
-
Venture Capital V, L.P.Vers...,
-
Capital Viii, Llc Vivo Capi...,
-
James Hassard,
Chief Commercial Officer -
Jack Nielsen,
Director -
Coelho Rogerio Vivaldi,
-
Dana Pizzuti,
Chief Med and Dev Officer -
Stephen F. Betz,
Chief Scientific Officer -
Caren Deardorf,